(19)
(11) EP 3 889 254 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.10.2024 Bulletin 2024/40

(45) Mention of the grant of the patent:
14.08.2024 Bulletin 2024/33

(21) Application number: 21158530.2

(22) Date of filing: 09.06.2011
(51) International Patent Classification (IPC): 
C12N 9/12(2006.01)
A61P 35/02(2006.01)
C12Q 1/6886(2018.01)
 A61P 35/00(2006.01)
A61P 35/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 9/1205; C12Q 2600/106; C12Q 2600/136; C12Q 2600/156; C12Y 207/12002; C12Q 1/6886; A61P 35/00; A61P 35/02; A61P 35/04

(54)

A MEK1 MUTATION CONFERRING RESISTANCE TO RAF AND MEK INHIBITORS

MEK1-MUTATION FÜR RESISTENZ GEGENÜBER RAF- UND MEK-INHIBITOREN

MUTATION DE MEK1 CONFÉRANT UNE RÉSISTANCE À DES INHIBITEURS DE RAF ET DE MEK

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.06.2010 US 35295910 P

(43) Date of publication of application:
06.10.2021 Bulletin 2021/40

(62) Application number of the earlier application in accordance with Art. 76 EPC:
17201390.6 / 3333259
11735711.1 / 2580322

(73) Proprietor: Dana-Farber Cancer Institute, Inc.
Boston, MA 02215 (US)

(72) Inventors:
  • GARRAWAY, Levi A
    Newton, MA 02460 (US)
  • EMERY, Caroline
    Brighton, MA 02135 (US)
  • WAGLE, Nikhil
    Brookline, MA 02446 (US)

(74) Representative: D Young & Co LLP 
3 Noble Street
London EC2V 7BQ
London EC2V 7BQ (GB)


(56) References cited: : 
WO-A1-2008/120004
   
  • EMERY C M ET AL: "MEK1 mutations confer resistance to MEK and B-RAF inhibition", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 48, 1 December 2009 (2009-12-01), NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, pages 20411 - 20416, XP002569027, ISSN: 0027-8424, DOI: 10.1073/PNAS.0905833106
  • WAGLE NIKHIL ET AL: "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 29, no. 22, 1 August 2011 (2011-08-01), pages 3085 - 3096, XP009151363, ISSN: 1527-7755
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).